INTRODUCTION
Gastric cancer remains one of the leading causes of cancer deaths worldwide. Complete surgical resection provides the only curative chance for gastric cancer. In spite of recent improvements in overall survival rates, the mortality of patients remains high because many patients are diagnosed in the advanced stages of gastric cancer [1] . In spite of many effective chemotherapeutic agents and various administration methods, it has been shown that gastric cancer is one of the malignant diseases that is less sensitive to chemotherapy [2] .
TS-1 is a novel, oral fluorouracil formation composed of tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio 1:0.4:1, based on biochemical modulation of 5-fluorouracil [3] . Late phase II clinical trials have already been conducted in gastric cancer patients with a response rate of 44.6%. On the strength of such encouraging results, gastric cancer as an indication for the use of TS-1 was approved in March 1999. As TS-1 is effective when administered orally and has a low incidence of severe adverse effects, TS-1 is expected to be suitable for outpatient chemotherapy [4] .
We report the first case of long-term drug retention of TS-1 with a fatal adverse reaction causing interstitial lung disease (ILD). A chest X-ray showed increased interstitial shadows in both lungs and a chest computed tomography scan also revealed aggravated ground glass opacities and reticular honeycomb lesions in both lower lung fields.
because of the patient's worsening pulmonary symptoms and revealed progression of diffuse ILD (Fig. 2) . In spite of the aggressive management in intensive care unit and the intravenous administration of corticosteroids with 125 mg of methylprednisolone, her symptoms did not improve.
The pathologic organism was not verified by sputum microbiologic study. She died of pulmonary failure due to progression of interstitial pneumonia on 11 January 2010.
An autopsy was not performed.
DISCUSSION
Instead of the conventional high-dose intravenous administration that has as a goal of total cell killing, the concept of how to continue drug administration safely for long periods and ultimately prolong survival without compromising quality of life is now the standard chemotherapeutic approach for gastric cancer. Thus, TS-1 could be an attractive anti-cancer agent for gastric cancer, with a high response rate and low toxicity. The possibility of outpatient use of TS-1 has increased the convenience for both physicians and patients [3, 4] .
Several randomized trials have shown that TS-1 is an excellent oral anti-cancer drug for the treatment of advanced gastric cancer, and have suggested that this agent may be useful for neoadjuvant chemotherapy [6] . (CDDP) regimen is currently used widely due to its high efficacy [2] , and our patient also received it initially.
Drug-induced ILD is not uncommon, ranging from benign infiltration to life-threatening acute respiratory distress syndrome. These clinical patterns differ depending on the patient's illness and drug factors, including the type of drug [7] . A comprehensive knowledge of the mechanisms involved in the development of drug-induced ILD has not been achieved. The patient with suspected ILD presents a diagnostic challenge to physicians. Clinical, radiologic, and pathologic observations are necessary to exclude other conditions with similar symptoms, such as lymphangitis carcinomatosis, pneumonia, allergy, cardiogenic edema, and pulmonary hemorrhage. Thus, a detailed recent drug history is helpful to make the diagnosis.
There has been only one report of ILD induced by TS-1 in patients with gastric cancer [8] . ILD was aggravated af- Urinary excretion within 12 hours after administration of TS-1 was 47.4% for CDHP, and 7.0% for 5-FU. Urinary excretion within 72 hours was 52.8% for CDHP, and 7.4% for 5-FU. Urinary excretion was nearly completed by 12 hours and large amounts of 5-FU excrete as CO2 by lung [9] . Therefore, ILD is thought to be caused by a misdirected immune or healing reaction to TS-1 for long time. We assumed that long-term retention and reaction of the drug in the lung would alter the lung parenchyma irreversibly, and might impair resolution on discontinuation of the drug with multiple therapies, including the administration of corticosteroids. Thus, the only method to avoid the progression to life-threatening ILD is prevention or early detection of disease.
One study showed that interstitial shadows on radiologic findings are associated with a risk of ILD in patients with such findings [10] . Therefore, we recommended that a pulmonary radiologic evaluation should be performed before the start of TS-1 for the prevention of ILD.
Moreover, routine pulmonary evaluation is inevitable in patients who are prescribed TS-1 to detect the progression of ILD at an early stage, thus providing an opportunity to recover and reduce the drug-associated morbidity and mortality.
In conclusion, TS-1 is a proven anti-cancer agent for gastric cancer with a high response rate and low toxicity. The outpatient use of TS-1 is thus attractive for both physicians and patients. Occasionally, TS-1 can cause irreversible ILD with a long-term retention in the lung that the outcome can be life-threatening. Thus, we have to keep in mind the potential for drug toxicity in the form of ILD. Pulmonary evaluation by meticulous history taking and physical examination and chest X-ray is advisable in patients who are prescribed TS-1 so that it may contribute to a reduction in its morbidity and mortality. We should identity the mechanism underlying the fatal complication of TS-1 and clarify which component of the drug is mostly related to it.
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